These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21074348)

  • 21. Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer.
    Köstler WJ; Steger GG; Soleiman A; Schwab B; Singer CF; Tomek S; Brodowicz T; Krainer M; Wiltschke C; Horvat R; Jakesz R; Zielinski CC
    Anticancer Res; 2004; 24(2C):1127-30. PubMed ID: 15154635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V; Witzel I; Pantel K; Krenkel S; Lück HJ; Neumann R; Keller T; Dittmer J; Jänicke F; Thomssen C
    Anticancer Res; 2006; 26(2B):1479-87. PubMed ID: 16619561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
    Esteva FJ; Valero V; Booser D; Guerra LT; Murray JL; Pusztai L; Cristofanilli M; Arun B; Esmaeli B; Fritsche HA; Sneige N; Smith TL; Hortobagyi GN
    J Clin Oncol; 2002 Apr; 20(7):1800-8. PubMed ID: 11919237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum HER-2/neu in the management of breast cancer patients.
    Lüftner D; Lüke C; Possinger K
    Clin Biochem; 2003 Jun; 36(4):233-40. PubMed ID: 12810150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic and predictive values of ECD-HER-2.
    Hait WN
    Clin Cancer Res; 2001 Sep; 7(9):2601-4. PubMed ID: 11555568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of trastuzumab on tumor cell lines shedding high or low level of HER-2 ECD].
    Liu CY; Yang W; Li JF; Sun SL; Shou CC
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):101-5. PubMed ID: 17645842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
    J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of plasma HER2 copy number in cell-free DNA of breast cancer patients: a comparison with HER2 extracellular domain protein level in serum.
    Qui S; Takeshita T; Sueta A; Tomiguchi M; Goto-Yamaguchi L; Hidaka K; Suzu I; Yamamoto Y; Iwase H
    Breast Cancer; 2021 May; 28(3):746-754. PubMed ID: 33538993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating levels of HER-2/neu oncoprotein in breast cancer.
    Molina R; Escudero JM; Muñoz M; Augé JM; Filella X
    Clin Chem Lab Med; 2012 Jan; 50(1):5-21. PubMed ID: 22505536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
    Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
    Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?
    Badzek S; Kelovic VL; Plestina S; Humar I; Veir Z; Mihaljevic Z
    Wien Klin Wochenschr; 2011 Dec; 123(23-24):726-31. PubMed ID: 22113445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Circulating proteinic biomarkers and breast cancer].
    Mathelin C; Koehl C; Rio MC
    Gynecol Obstet Fertil; 2006; 34(7-8):638-46. PubMed ID: 16876456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours.
    Pallud C; Guinebretiere JM; Guepratte S; Hacene K; Neumann R; Carney W; Pichon MF
    Anticancer Res; 2005; 25(2B):1433-40. PubMed ID: 15865102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.
    Singer CF; Köstler WJ; Hudelist G
    Biochim Biophys Acta; 2008 Dec; 1786(2):105-13. PubMed ID: 18375208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
    Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
    Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Extracellular domain of HER-2 as a prognostic factor in osteosarcoma. A pilot study].
    Ługowska I; Woźniak W; Ambroszkiewicz J; Gajewska J; Szamotulska K
    Med Wieku Rozwoj; 2009; 13(3):201-8. PubMed ID: 20081266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meaningful interpretation of serum HER2 ECD levels requires clear patient clinical background, and serves several functions in the efficient management of breast cancer patients.
    Wang T; Zhou J; Zhang S; Bian L; Hu H; Xu C; Hao X; Liu B; Ye Q; Liu Y; Jiang Z
    Clin Chim Acta; 2016 Jul; 458():23-9. PubMed ID: 27109901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between serum HER-2 oncoprotein and patients with breast cancer.
    Yuan P; Xu BH; Chu DT
    Chin Med Sci J; 2004 Sep; 19(3):212-5. PubMed ID: 15506651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Portable detection of serum HER-2 in breast cancer by a pressure-based platform.
    Tao Q; Wu X; Lin Q; Zheng H; Yang W; Liu D; Yang CJ; Ji T
    Anal Bioanal Chem; 2018 Nov; 410(28):7489-7498. PubMed ID: 30232524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
    Jensen BV; Johansen JS; Price PA
    Clin Cancer Res; 2003 Oct; 9(12):4423-34. PubMed ID: 14555515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.